NCT02918006View on ClinicalTrials.gov

A Phase 2 Influenza A Challenge Study Following Oral Administration of an H1N1 HA Ad-Vector Seasonal Flu Vaccine

PHASE2CompletedINTERVENTIONAL
Enrollment

179

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

August 8, 2017

Study Completion Date

January 19, 2018

Conditions
Influenza
Interventions
BIOLOGICAL

VXA-A1.1

Enteric coated oral vaccine tablet

BIOLOGICAL

Fluzone®

Fluzone Quadravalent (Fluzone®) influenza vaccine (QIV) suspension for intramuscular (IM) injection

OTHER

Placebo Tablets

Placebo tablets similar in size, color and number to the active oral tablet vaccine drug product

OTHER

Saline Solution for Placebo IM Injection

Trial Locations (1)

92626

WCCT Global, Costa Mesa

Sponsors

Lead Sponsor

Vaxart
All Listed Sponsors
collaborator

Biomedical Advanced Research and Development Authority

FED

lead

Vaxart

INDUSTRY

NCT02918006 - A Phase 2 Influenza A Challenge Study Following Oral Administration of an H1N1 HA Ad-Vector Seasonal Flu Vaccine | Biotech Hunter | Biotech Hunter